Rare Disease Report
Physicians
Physicians
Patients & Caregivers

Questions about Eteplirsen

MAY 26, 2016
James Radke, PhD
These are the questions I have been asked over and over and over again recently.

Will eteplirsen get approved?

I don’t know.

Should I buy stock in Sarepta?

I don’t know.

How much do you think the share price will fluctuate over the next couple of weeks?

I don’t know.

When will the FDA make a decision?

I don’t know.

Many think the delay by the FDA is a good sign that the drug will get approved. Is that true?

I don’t know.

Many think the delay by the FDA means the drug will not get approved. Is that true?

I don’t know.

If the FDA approves the eteplirsen, will it be conditional on more studies being done?

I don’t know.

If the FDA does not approve eteplirsen, what will Sarepta do?

I don’t know.

If the FDA does not approve eteplirsen, what will the patients and advocates do?

Continue to look for additional treatment options.

If the FDA does approve eteplirsen, what will the patients and advocates do?

Continue to look for additional treatment options.

Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.